Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of S-524101 in the Pediatric Patients with Perennial Allergic Rhinitis

Next Previous
X
Search
Trial Profile

A Phase 3 Study of S-524101 in the Pediatric Patients with Perennial Allergic Rhinitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs S 524101 (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Shionogi

    • Most Recent Events

    • 16 Feb 2018 According to a Stallergenes Greer media release, based on the data of this study, Shionogi has received an approval for the ACTAIR, an allergy immunotherapy sublingual tablet for the treatment of house dust mite (HDM) induced allergic rhinitis, to treat patients under the age of 12. The drug was already approved for HDM in Japan in patients above the age of 12 years since march 2015.
    • 15 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 28 Mar 2017 According to a Stallergenes Greer plc media release, a New Drug Application (NDA) for ACTAIR, an investigational allergy immunotherapy sublingual tablet, for the treatment of house dust mite (HDM) induced allergic rhinitis in children 5 to 11 years old has been submitted in Japan. The submission is based on data from this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top